Treatment of hyperfunctional lines of the face with Botulinum toxin A

Dermatologic Surgery

Volumn 24, Issue 11, 1998, Pages 1198-1205

  Binder, William J ^a,c   Blitzer, Andrew ^b   Brin, Mitchell F ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; POLITEF;

ARTICLE; BLEPHAROSPASM; DRUG MECHANISM; DRUG SAFETY; ESTHETIC SURGERY; EYEBROW; FACE SURGERY; FACIAL EXPRESSION; HUMAN; HUMAN TISSUE; INJECTION PAIN; MAJOR CLINICAL STUDY; OPHTHALMOPLEGIA; PRIORITY JOURNAL; RELIABILITY; SURGICAL TECHNIQUE;

EID: 0031724963     PISSN: 10760512     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-4725.1998.tb04098.x     Document Type: Article

References (32)

1. Scott AB, Kennedy RA, Stubbs HA. Botulinum toxin A injection is a treatment for blepharospasm. Arch Ophthal 1984;103:347.
2. Brin MF, Fahn S, Moskowitz C, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 1987;2:237-54.
3. Kang U, Greene P, Fahn S, et al. Double-blind placebo-controlled study of botulinum toxin injection for torticollis. Neurology 1988; 38:244.
4. Brin MF, Fahn S, Moskowitz CB, Blitzer A, Friedman A, Shale HM. Injections of botulinum toxin for the treatment of focal dystonia. Neurology 1986;36 (Suppl 1):176.
5. Brin MF, Fahn S, Moskowitz CB, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Adv Neurol 1988;599-608.
6. Blitzer A, Brin M, Fahn S, Lovelace RE. The use of botulinum toxin in the treatment of focal laryngeal dystonia (spastic dysphonia). Laryngoscope 1988;98:193-7.
7. Blitzer A, Brin MF, Fahn S. Botulinum toxin injection for the treatment of oromandibular dystonia. Ann Otol Rhinol Laryngol 1989;98:93-7.
8. Brin MF, Blitzer A, Fahn S, Lovelace RE. Adductor laryngeal dystonia: treatment with local injections of botulinum toxin (Botox). Neurology 1988;37(suppl 1):244.
9. Brin MF Blitzer A, Fahn S, et al. Adductor laryngeal dystonia (spastic dysphonia): treatment with local injections of botulinum toxin (Botox). Mov Disord 1989;4:287-96.
10. Blitzer A, Brin MF. Laryngeal dystonia: a series with botulinum toxin therapy. Ann Otol Rhinol Laryngol 1991;100:85-90.
11. Brin MF, Blitzer A, Greene PE, Fahn S. Botulinum toxin therapy for the treatment of oromandibular dystonia (OMD). Ann Otol Rhinol Laryngol 1989:93-7.
12. Blitzer A, Brin MF, Stewart C, Fahn S. Abductor laryngeal dystonia: A series treated with botulinum toxin. Laryngoscope 1992; 102:163-7.
13. Blitzer A, Brin MF, Fahn S. Botulinum toxin injections for lingual dystonia. Laryngoscope 1991;101:799.
14. Blitzer A, Brin MF, Keen MS, Aviv JS. Botulinum toxin for the treatment of hyperfunctional lines of the face. Arch Otolaryngol Head Neck Surg 1993;119:1018-23.
15. Keen MS, Blitzer A, Aviv JE, et al. Botulinum toxin A for hyperkinetic facial lines: results of a double blind placebo controlled study. Plast Reconstr Surg 1994;94:94-99.
16. Keen M, Kopelman JE, Aviv JE, Binder W, Brin MF, Blitzer A. Botulinum toxin A: a novel method to remove periorbital wrinkles. Facial Plast Surg 1994;10:141-6.
17. Carruthers A, Carruthers J. Aesthetic indications for botulinum toxin injections. Plast Reconstr Surg 1995;95:427-8.
18. Pitanguy I. Indications for treatment of frontal and glabellar wrinkles in an analysis of 3,404 consecutive cases of rhytidectomy. Plast Reconstr Surg 1981;67:157-66.
19. Pollack SV. Silicone, fibrel, and collagen implantation for facial lines and wrinkles. J Dermatol Surg Oncol 1990;16:957-61.
20. Blitzer A, Binder W, Aviv J, Keen M, Brin M. The management of hyperfunctional facial lines with botulinum toxin: a collaborative study of 210 injection sites in 162 patients. Arch Otolaryngol Head Neck Surg 1997;123:389-92.
21. Simpson LL. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev 1981;33:155-88.
22. Simpson LL. Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther 1980;212:16-21.
23. Simpson LL, Dasgupta BR. Botulinum neurotoxin type E: studies on mechanism of action and on structure activity relationships. J Pharmacol Exp Ther 1983;224:135-40.
24. 125I-labelled botulinum neurotoxins with nerve terminals. I. Ultrastrucrural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves. J Cell Biol 1986;103:521-34.
25. Borodic GE, Ferranter R. Orbicularis muscle histology after repetitive injections of botulinum A toxin. Presented at the annual meeting of the American Academy of Ophthalmology, Atlanta, Georgia, 1990.
26. Scott AB, Kennedy RA, Stubbs HA. Botulinum toxin. Presented at the annual meeting of the American Academy of Ophthalmology, Atlanta, Georgia, 1990.
27. Hambleton P, Moore AP. Botulinum neurotoxins: origin, structure, molecular actions, and antibody. In: Moore P, ed. Handbook of Botulinum Toxin Treatment. Oxford: Blackwell Science, Ltd., 1995:16-27.
28. Tosoy EA, Bukley EG. Treatment of blepharospasm with botulinum toxin. Am J Ophthal 1985;99:176.
29. Maoriello JA Jr. Blepharospasm Meige's syndrome and hemifacial spasm: treatment with botulinum toxin. Neurology 1985;35:1499.
30. National Institutes of Health Consensus Development Conference. Clinical use of Botulinum Toxin. 1990;8:1-20.
31. Borodic G, Johnson E, Goodnough M, Schantz E. Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology 1996;46:26-9.
32. Lange DH, et al. Distal effects of locally injected Botulinum toxin: incidences and effects. Adv Neurology 1988;50:609.